

10/070963

1019 Rec'd PCT/PTO 13 MAR 2002

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Serial No.	Group Art Unit	Filing Date MAR 13 2002	Atty. Docket No. Le A 33 965	
INFORMATION DISCLOSURE CITATION		Applicant(s) BISCHOFF, et al.				
U.S. PATENT DOCUMENTS						
*		DOCUMENT NO.	DATE MM/DD/YY	NAME	CLASS S U B - CLASS	FILING DATE IF APPROPRIATE

✓	U1	5	0	0	6	5	3	0.	04/09/91	Angerbauer et al.	514	277	01/17/89
✓													
✓													
✓													
✓													
✓													
✓													
✓													

FOREIGN PATENT DOCUMENTS

*		DOCUMENT NO.							DATE DD/MM/YY	COUNTRY	PRIMARY CLASS	S U B - CLASS	TRANSLATION		
													YES	NO	
✓	F1	9	9	2	4	4	3	3	20/05/99	WO	—	—	—	—	X
✓	F2	9	6	1	6	6	4	4	06/06/96	WO	—	—	—	—	
✓	F3	9	4	2	8	9	0	2	22/12/94	WO	—	—	—	—	
✓	F4	0	3	2	5	1	3	0	26/07/89	EP	—	—	—	—	X

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

✓	R2	Cheitlin, M. D., Hutter, A. M., Brindis, R. G., Ganz, P., Kaul, S., Russell, R. O., Zusman, R. M., "Use of Sildenafil (Viagra) in Patients with Cardiovascular Disease", Circulation, 99: 168-177 (1999)
✓	R3	Laufs, U., La Fata, V., Plutzky, J., Liao, J. K., "Upregulation of Endothelial Nitric Oxide Synthase by HMG CoA Reductase Inhibitors", Circulation, 97: 1129-1135 (1998)
✓	R4	Watanabe, M., Koike, H., Ishiba, T., Okada, T., Seo, S., Hirai, K., "Synthesis and Biological Activity of Methanesulfonamide Pyrimidine- and N-Methanesulfonyl Pyrrole-Substituted 3,5-Dihydroxy-6-heptenoates, a Novel Series of HMG-CoA Reductase Inhibitors", Bioorganic & Medicinal Chemistry, 5(2): 437-444 (1997)

EXAMINER		DATE CONSIDERED	11/28/03
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Form PTO-449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Serial No. 10/070,963	Group Art Unit 1614	Filing Date 06/28/2002	Atty. Docket No. Le A 33 965
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION		Applicant(s) Bischoff, et al.			


RECEIVED


OCT 15 2002

U.S. PATENT DOCUMENTS													
*	DOCUMENT NO.							DATE MM/DD/YY	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE	
Duplicated	U2	5	0	0	0	5	3	0	04/09/91	Angerbauer et al.	514	277	01/17/89
	U3	5	1	7	7	0	8	0	01/05/93	Angerbauer, et al.	514	277	11/26/91

FOREIGN PATENT DOCUMENTS															
		DOCUMENT NO.							DATE DD/MM/YY	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION		
		F5	0	4	6	3	7	5	6	02/01/92	EP	—	—	YES	NO
		F6	0	5	2	6	0	0	4	03/02/93	EP	—	—		
		F7	9	9	1	1	2	6	3	11/03/99	WO	—	—		
		F8	0	4	9	1	2	2	6	24/06/92	EP	—	—		
		F9	0	7	0	2	5	5	5	11/03/98	EP	—	—		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)										
	R5	Turko, I., Ballard, S., Francis, S., Corbin, J., "Inhibition of Cyclic GMP-Binding Cyclic GMP-Specific Phosphodiesterase (Type 5) by Sildenafil and Related Compounds", Molecular Pharmacology, <u>56</u> : 124-130 (1999)								
	R6	Trigo-Rocha, F., Aronson, W., Hohenfellner, M., Ignarro, L., Rajfer, J., Lue, T., "Nitric Oxide and cGMP: Mediators of Pelvic Nerve-Stimulated Erection in Dogs", Am. J. Physiol., <u>264</u> : H419-H422 (1993)								
	R7	Bush, P., Aronson, W., Buga, G., Rajfer, J., Ignarro, L., "Nitric Oxide Is A Potent Relaxant of Human and Rabbit Corpus Cavernosum", J. Urology, <u>147</u> : 1650-1655 (1992)								
	R8	Rajfer, J., Aronson, W., Bush, P., Dorey, F., Ignarro, L., "Nitric Oxide As a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic, Noncholinergic Neurotransmission", N.E. J. Medicine, <u>326</u> : 90-94 (1992)								
	R9	Sohn, M., Kohler, H., Handt, S., Sikora, R., Bosshardt, R., Wein, F., Jakse, G., "The Role of Intracavernosal Eicosanoids and Endotheline During Drug-Induced Erections", Int. J. Impotence Res., <u>4</u> : Suppl. 2, A11 (1992)								

EXAMINER		DATE CONSIDERED	11/28/03
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			



RECEIVED

OCT 15 2002

TECH CENTER 1600/2900

	(1992)
R10	Murray, K., "Phosphodiesterase V _A Inhibitors", Drugs, News Perspectives, <u>6</u> : 150-156 (1993)
R11	Andersson, K., Wagner, G., "Physiology of Penile Erection", Physiological Reviews, <u>75</u> : 191-236 (1995)
R12	Meinhardt, W., Kropman, R., Vermeij, P., Lycklama a Nijeholt, A., Zwartendijk, J., "The Influence of Medication on Erectile Function", Int. J. of Impotence, <u>9</u> : 17-26 (1997)
R13	Beavo, J., Reifsnyder, D., "Primary Sequence of Cyclic Nucleotide Phosphodiesterase Isozymes and the Design of Selective Inhibitors", TIPS Reviews, <u>11</u> : 150-155 (1990)
R14	Dujovne, C., "New Lipid Lowering Drugs and New Effects of Old Drugs", Curr. Opinions in Lipidology, <u>8</u> : 362-368 (1997)
R15	El-Sakka, A., Lin, C., Chui, R., Dahiya, R., Lue, T., "Effects of Diabetes on Nitric Oxide Synthase and Growth Factor Genes and Protein Expression in an Animal Model", Int. J. Impotence Research, <u>11</u> : 123-132 (1999)
R16	Srilatha, B., Adaikan, P., Ng, S., Arulkumaran, S., "Elevated Low-Density Lipoprotein Cholesterol (LDL-C) Enhances Pro-Erectile Neurotransmission in the Corpus Cavernosum", Int. J. Impotence Research, <u>11</u> : 159-165 (1999)
R17	Thompson, G., Naoumova, R., "New Prospects For Lipid-Lowering Drugs", Exp. Opin. Invest. Drugs, <u>7</u> : 715-727 (1998)
R18	Angerbauer, R., Bischoff, H., Steinke, W., Ritter, W., "BAY W 6228 Rivastatin", Drugs of the Future, <u>19</u> : 537-541 (1994)
R19	Takeda, K., "BAY-w-6228 Rivastatin", Drugs of the Future, <u>20</u> : 611 (1995)
R20	Takeda, K., "BAY-w-6228 Cerivastatin Sodium", Drugs of the Future, <u>21</u> : 642 (1996)
R21	Boolell, M., Allen, M., Ballard, S., Gepi-Attee, S., Muirhead, G., Naylor, A., Osterloh, I., Gingell, C., "Sildenafil: An Orally Active Type 5 Cyclic GMP-Specific Phosphodiesterase Inhibitor For the Treatment of Penile Erectile Dysfunction", Int. J. Impotence Research, <u>8</u> : 47-52 (1996)
R22	Manns, D., "HMG-CoA-Reduktase Hemmer Im Überblick", Pharmazie in Unserer Zeit, <u>28</u> : 147-152 (1999)

EXAMINER		DATE CONSIDERED 11/28/03
<p>* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		